Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Antiviral Therapy|September 2, 2016
Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trialsAkshanth R Polepally, Prajakta S Badri, Apurvasena Parikh, et al.Clinical Pharmacology and Therapeutics|July 7, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk MitigationTommy Li, Andrew Tredennick, Daniel Polhamus, et al.Acta Crystallographica. Section D, Biological Crystallography|November 22, 2011
Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillinOsheiza Abdulmalik, Mohini S Ghatge, Faik N Musayev, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung CancerD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung CarcinomaD Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.JTO Clinical and Research Reports|January 10, 2022
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLCD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.Leukemia & Lymphoma|June 18, 2025
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphomaDurga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, et al.Cancer Immunology, Immunotherapy : CII|July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaAntoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.Clinical Pharmacology and Therapeutics|May 16, 2024
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White PaperDivya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, et al.Pageof 3